ON January 4, 2023 Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, reported that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference held on January 9-12, 2023 in San Francisco and Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent will present on Wednesday, January 11, 2023 at 10:00am Pacific Standard Time (Press release, Innovent Biologics, JAN 4, 2023, View Source [SID1234625832]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A live webcast (audio) of the presentation can be accessed at:
View Source;kiosk=true
A replay of the webcast (active for up to 30 days ) and presentation slides will be available on the Innovent website – Investors & Media section following the live presentation:
View Source